Aileron Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
ADAR1 Capital Management, LLC and its manager Daniel Schneeberger have jointly filed a Schedule 13G, reporting beneficial ownership of 4,500,000 shares, representing 5.3% of Rein Therapeutics, Inc.'s common stock as of June 30, 2026.
Lynwood Capital Management Inc., Ben Shapiro, and Lynwood Opportunities Master Fund have reported beneficial ownership of 5.0% of Rein Therapeutics, Inc. common stock as of June 30, 2026.
Laurence W. Lytton has reported beneficial ownership of 4,238,628 shares, representing 4.9% of Rein Therapeutics, Inc. common stock, as of June 30, 2026.
Voss Capital and affiliated entities report beneficial ownership of 6.6% of Rein Therapeutics' common stock as of June 30, 2026.
A group of investment funds managed by Bios Capital Management has reported a 9.99% beneficial ownership stake in Rein Therapeutics, Inc.
Lynwood Capital Management and associated entities have reported a 6.1% beneficial ownership stake in Rein Therapeutics, Inc. following a recent equity offering.
Funicular Funds, LP, Cable Car Capital, LP, and Jacob Ma-Weaver have filed a Schedule 13G reporting a 6.7% beneficial ownership stake in Rein Therapeutics, Inc.
Laurence W. Lytton has reported beneficial ownership of 4,500,000 shares, representing 5.8% of the common stock of Rein Therapeutics, Inc.
Voss Capital and its affiliates have reported an aggregate beneficial ownership of 11.3% in Rein Therapeutics, Inc. common stock.
Voss Capital, along with its affiliated funds and managing member Travis W. Cocke, has disclosed a combined beneficial ownership of 5.6% of Rein Therapeutics, Inc.'s common stock.